These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35144181)

  • 1. The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study.
    Metwally AS; El-Sheikh SMA; Galal AAA
    Diabetes Metab Syndr; 2022 Feb; 16(2):102410. PubMed ID: 35144181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of diabetes mellitus on rifampicin's plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study.
    El-Sheikh SMA; Metwally AS; Galal AAA
    Therapie; 2023; 78(3):313-324. PubMed ID: 35717337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis.
    Huang D; Wang Y; Wang Y; Liang Z
    Ann Palliat Med; 2020 Mar; 9(2):152-162. PubMed ID: 32268768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
    Fonseca AAD; Pinto ACG; Paixão TPD; Albério CAA; Vieira JLF
    Braz J Infect Dis; 2020; 24(4):352-355. PubMed ID: 32535111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.
    Te Brake LHM; Yunivita V; Livia R; Soetedjo N; van Ewijk-Beneken Kolmer E; Koenderink JB; Burger DM; Santoso P; van Crevel R; Alisjahbana B; Aarnoutse RE; Ruslami R;
    Clin Pharmacol Ther; 2019 Mar; 105(3):730-737. PubMed ID: 30222857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.
    Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S
    J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of oral rifampicin in AIDS patients.
    Jaruratanasirikul S
    J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
    Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
    Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.
    Stott KE; Pertinez H; Sturkenboom MGG; Boeree MJ; Aarnoutse R; Ramachandran G; Requena-Méndez A; Peloquin C; Koegelenberg CFN; Alffenaar JWC; Ruslami R; Tostmann A; Swaminathan S; McIlleron H; Davies G
    J Antimicrob Chemother; 2018 Sep; 73(9):2305-2313. PubMed ID: 29701775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
    Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
    Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?
    Zheng C; Hu X; Zhao L; Hu M; Gao F
    Drug Des Devel Ther; 2017; 11():2957-2968. PubMed ID: 29066867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages.
    Tukulula M; Gouveia L; Paixao P; Hayeshi R; Naicker B; Dube A
    Pharm Res; 2018 Mar; 35(6):111. PubMed ID: 29600438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
    Ruslami R; Nijland HM; Adhiarta IG; Kariadi SH; Alisjahbana B; Aarnoutse RE; van Crevel R
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1068-74. PubMed ID: 20038625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
    J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.